PT3092246T - Fragmentos mutantes de ospa e métodos e utilizações que se relacionam com os mesmos - Google Patents

Fragmentos mutantes de ospa e métodos e utilizações que se relacionam com os mesmos

Info

Publication number: PT3092246T
Authority: PT; Portugal
Prior art keywords: ospa; methods; mutant fragments; uses relating; relating
Prior art date: 2014-01-09

Application number

PT15703228T

Other languages

English (en)

Inventor

Lundberg Urban

Schüler Wolfgang

Original Assignee

Valneva Austria Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-09

Filing date

2015-01-09

Publication date

2019-07-19

2015-01-09 Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh

2019-07-19 Publication of PT3092246T publication Critical patent/PT3092246T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)

PT15703228T 2014-01-09 2015-01-09 Fragmentos mutantes de ospa e métodos e utilizações que se relacionam com os mesmos PT3092246T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP14150682		2014-01-09

Publications (1)

Publication Number	Publication Date
PT3092246T true PT3092246T (pt)	2019-07-19

Family

ID=49917594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT15703228T PT3092246T (pt)	2014-01-09	2015-01-09	Fragmentos mutantes de ospa e métodos e utilizações que se relacionam com os mesmos

Country Status (24)

Country	Link
US (4)	US9975927B2 (pt)
EP (2)	EP3564257A1 (pt)
JP (1)	JP6505110B2 (pt)
KR (1)	KR102460165B1 (pt)
CN (1)	CN105980398B (pt)
AU (1)	AU2015205520B2 (pt)
BR (2)	BR122023024315A2 (pt)
CA (1)	CA2931110A1 (pt)
CY (1)	CY1121734T1 (pt)
DK (1)	DK3092246T3 (pt)
EA (1)	EA034554B1 (pt)
ES (1)	ES2740985T3 (pt)
HR (1)	HRP20191086T1 (pt)
HU (1)	HUE043779T2 (pt)
LT (1)	LT3092246T (pt)
MX (1)	MX369195B (pt)
NZ (1)	NZ721015A (pt)
PL (1)	PL3092246T3 (pt)
PT (1)	PT3092246T (pt)
RS (1)	RS59075B1 (pt)
SI (1)	SI3092246T1 (pt)
TR (1)	TR201910117T4 (pt)
WO (1)	WO2015104396A1 (pt)
ZA (1)	ZA201602690B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8986704B2 (en)	2012-07-06	2015-03-24	Valneva Austria Gmbh	Mutant fragments of OspA and methods and uses relating thereto
PL3092246T3 (pl)	2014-01-09	2019-09-30	Valneva Austria Gmbh	Zmutowane fragmenty OspA oraz sposoby i zastosowania z nimi związane
CA3059817A1 (en)	2017-04-13	2018-10-18	Valneva Austria Gmbh	Multivalent ospa polypeptides and methods and uses relating thereto
CN110483624B (zh) *	2019-08-22	2021-02-09	中国疾病预防控制中心传染病预防控制所	伽氏疏螺旋体OspA蛋白C端肽段及其应用
WO2021207615A1 (en)	2020-04-09	2021-10-14	Valneva Austria Gmbh	Compositions comprising three ospa fusion proteins for medical use
WO2021205022A1 (en)	2020-04-09	2021-10-14	Valneva Austria Gmbh	Improved methods of producing a lipidated protein
WO2023212520A1 (en)	2022-04-25	2023-11-02	Pfizer Inc.	Compositions and methods for eliciting an immune response protective against lyme disease
WO2024050512A2 (en) *	2022-09-02	2024-03-07	The Medical College Of Wisconsin, Inc.	Use of immunogenic t cell epitopes for lyme disease vaccination and diagnosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7008625B2 (en)	1993-11-01	2006-03-07	Research Foundation Of The State University Of New York	Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en)	1993-11-01	2001-06-19	Research Foundation State University Of New York	Chimeric proteins comprising borrelia polypeptides and uses therefor
DK1311540T3 (da)	2000-08-18	2008-04-28	Brookhaven Sciences Ass Llc	Ændret OspA af Borrelia Burgdorferi
UA89481C2 (uk)	2003-09-30	2010-02-10	Центокор, Инк.	Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
WO2008031133A2 (en)	2006-09-15	2008-03-20	Intercell Ag	Borrelia antigens
ES2675915T3 (es)	2006-09-26	2018-07-13	Infectious Disease Research Institute	Composición de vacuna que contiene un adyuvante sintético
EP3705133B1 (en)	2010-05-14	2024-06-26	Baxalta Incorporated	Ospa chimeras and use thereof in vaccines
TWI507413B (zh)	2010-11-15	2015-11-11	Nat Health Research Institutes	脂質化多抗原表位疫苗
TW201221642A (en)	2010-11-15	2012-06-01	Nat Health Research Institutes	Method of producing lipidated polypeptides
US8986704B2 (en)	2012-07-06	2015-03-24	Valneva Austria Gmbh	Mutant fragments of OspA and methods and uses relating thereto
PL3092246T3 (pl)	2014-01-09	2019-09-30	Valneva Austria Gmbh	Zmutowane fragmenty OspA oraz sposoby i zastosowania z nimi związane
CZ2014320A3 (cs)	2014-05-09	2015-11-18	VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i.	Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
CA3059817A1 (en)	2017-04-13	2018-10-18	Valneva Austria Gmbh	Multivalent ospa polypeptides and methods and uses relating thereto

2015
- 2015-01-09 PL PL15703228T patent/PL3092246T3/pl unknown
- 2015-01-09 ES ES15703228T patent/ES2740985T3/es active Active
- 2015-01-09 DK DK15703228.5T patent/DK3092246T3/da active
- 2015-01-09 BR BR122023024315-3A patent/BR122023024315A2/pt unknown
- 2015-01-09 RS RS20190970A patent/RS59075B1/sr unknown
- 2015-01-09 KR KR1020167015981A patent/KR102460165B1/ko active IP Right Grant
- 2015-01-09 WO PCT/EP2015/050365 patent/WO2015104396A1/en active Application Filing
- 2015-01-09 US US15/110,151 patent/US9975927B2/en active Active
- 2015-01-09 JP JP2016541706A patent/JP6505110B2/ja active Active
- 2015-01-09 LT LTEP15703228.5T patent/LT3092246T/lt unknown
- 2015-01-09 EP EP19177679.8A patent/EP3564257A1/en active Pending
- 2015-01-09 EP EP15703228.5A patent/EP3092246B1/en active Active
- 2015-01-09 AU AU2015205520A patent/AU2015205520B2/en active Active
- 2015-01-09 BR BR112016015678A patent/BR112016015678B1/pt active IP Right Grant
- 2015-01-09 HU HUE15703228A patent/HUE043779T2/hu unknown
- 2015-01-09 PT PT15703228T patent/PT3092246T/pt unknown
- 2015-01-09 CN CN201580003319.2A patent/CN105980398B/zh active Active
- 2015-01-09 EA EA201691095A patent/EA034554B1/ru unknown
- 2015-01-09 NZ NZ721015A patent/NZ721015A/en unknown
- 2015-01-09 CA CA2931110A patent/CA2931110A1/en active Pending
- 2015-01-09 TR TR2019/10117T patent/TR201910117T4/tr unknown
- 2015-01-09 SI SI201530777T patent/SI3092246T1/sl unknown
- 2015-01-09 MX MX2016008989A patent/MX369195B/es active IP Right Grant
2016
- 2016-04-19 ZA ZA2016/02690A patent/ZA201602690B/en unknown
2018
- 2018-04-04 US US15/944,835 patent/US10766931B2/en active Active
2019
- 2019-06-17 HR HRP20191086 patent/HRP20191086T1/hr unknown
- 2019-06-27 CY CY20191100676T patent/CY1121734T1/el unknown
2020
- 2020-08-11 US US16/990,023 patent/US11572392B2/en active Active
2023
- 2023-01-06 US US18/150,971 patent/US20230322869A1/en active Pending

Also Published As

Publication number	Publication date
US20180362593A1 (en)	2018-12-20
US10766931B2 (en)	2020-09-08
HRP20191086T1 (hr)	2019-11-01
ES2740985T3 (es)	2020-02-07
AU2015205520B2 (en)	2017-06-29
EP3564257A1 (en)	2019-11-06
RS59075B1 (sr)	2019-09-30
US20230322869A1 (en)	2023-10-12
US11572392B2 (en)	2023-02-07
TR201910117T4 (tr)	2019-07-22
HUE043779T2 (hu)	2019-09-30
US20210054032A1 (en)	2021-02-25
EA034554B1 (ru)	2020-02-19
EP3092246A1 (en)	2016-11-16
ZA201602690B (en)	2017-09-27
JP6505110B2 (ja)	2019-04-24
PL3092246T3 (pl)	2019-09-30
MX2016008989A (es)	2016-10-04
SI3092246T1 (sl)	2019-08-30
US20160333056A1 (en)	2016-11-17
WO2015104396A1 (en)	2015-07-16
CN105980398B (zh)	2019-11-26
MX369195B (es)	2019-10-31
LT3092246T (lt)	2019-07-10
CY1121734T1 (el)	2020-07-31
BR122023024315A2 (pt)	2023-12-26
BR112016015678B1 (pt)	2024-02-06
AU2015205520A1 (en)	2016-06-30
CA2931110A1 (en)	2015-07-16
EP3092246B1 (en)	2019-06-05
BR112016015678A2 (pt)	2017-10-03
NZ721015A (en)	2017-09-29
KR20160102993A (ko)	2016-08-31
EA201691095A1 (ru)	2017-03-31
DK3092246T3 (da)	2019-07-15
US9975927B2 (en)	2018-05-22
CN105980398A (zh)	2016-09-28
KR102460165B1 (ko)	2022-10-28
JP2017503792A (ja)	2017-02-02

Publication	Publication Date	Title
IL286316A (en)	2021-10-31	New micro-dystrophins and related method of use
IL250415B (en)	2020-09-30	Antibodies against pd-l and methods of using them
HRP20191086T1 (hr)	2019-11-01	Mutantni ospa fragmenti i postupci i uporabe koji se na njih odnose
IL251988A0 (en)	2017-06-29	Compounds acting on glycans and methods of using them
IL254708A0 (en)	2017-11-30	Mutated transaminases and methods and uses relating thereto
GB201417828D0 (en)	2014-11-19	New methods and compositions
PT3089971T (pt)	2020-09-03	Compostos e métodos de utilização
EP3099493A4 (en)	2017-09-27	Printbars and methods of forming printbars
SG11201704473WA (en)	2017-06-29	New methods and uses
ZA201703881B (en)	2021-10-27	Pneumolysin mutants and methods of use thereof
ZA201606450B (en)	2019-12-18	Compounds and their methods of use
PL3223846T3 (pl)	2024-03-11	Kompozycje adiuwantowe i powiązane sposoby
HK1243404A1 (zh)	2018-07-13	色酰胺組合物和使用方法
GB201408091D0 (en)	2014-06-18	Methods and uses
GB201403697D0 (en)	2014-04-16	Compounds and methods of use
GB201419559D0 (en)	2014-12-17	Therapeutic compositions and methods
GB201416797D0 (en)	2014-11-05	Contianer and method of use thereof
AU2014905067A0 (en)	2015-01-22	Compositions and methods of use
GB201416073D0 (en)	2014-10-29	Methods and uses
GB201416086D0 (en)	2014-10-29	Methods and uses
AU2014902829A0 (en)	2014-08-07	Compositions and Methods of Use